Eton Pharmaceutical
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +137.4% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 6.9% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 39.5x | Better than 14% |
| Forward P/E | 21.8x | Better than 32% |
| Price / Sales | 13.1x | Better than 8% |
| P/E vs own 5-yr range | 85th pctl | Better than 22% |
Growth A+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 55.5% | Better than 96% |
| Free cash flow CAGR (3Y) | 71.1% | Better than 89% |
Profitability C-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 53.5% | Better than 67% |
| Operating margin | -1.1% | Better than 20% |
| Net margin | -5.8% | Better than 19% |
| Return on equity | -18.2% | Better than 17% |
| Return on invested capital | -7.6% | Better than 19% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -4.1% | Better than 64% |
| 6-month return | 86.7% | Better than 99% |
| 12-month return (ex latest month) | 203.9% | Better than 99% |
| Distance below 52-week high | 13.9% | Better than 75% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.6x | Better than 43% |
| Debt to assets | 33.7% | Better than 35% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 32.7% | Better than 52% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 61.36
- Open
- 61.00
- Day range
- 59.18 - 61.65
- Avg price
- 60.64
- Volume
- 562.66K
- Turnover
- 34.12M
- Turnover ratei
- 2.50%
- Volume ratioi
- 0.99
- Amplitudei
- 4.03%
- 52-week rangei
- 14.27 - 70.64
Valuation
- P/Ei
- -357.94
- P/E (TTM)i
- 39.51
- P/Bi
- 20.19
- EPSi
- -0.17
- Book value / shi
- 3.01
- Net profit
- -4.90M
- Net assets
- 86.93M
Share structure
- Market cap
- 1.76B
- Float capi
- 1.37B
- Shares out
- 28.84M
- Float sharesi
- 22.52M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-11-09
13.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+3.22M net over the window
Short interest
- Shares short
- 1.99M
- % of floati
- 6.95%
- Days to coveri
- 5.43
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Eton Pharmaceutical (ETON)?
Eton Pharmaceutical last traded at 60.85. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Eton Pharmaceutical's market cap?
About 1.76B.
What is the P/E ratio of Eton Pharmaceutical?
The trailing twelve-month P/E is 39.51. The Valuation tab shows it against the stock's own five-year range.
Does Eton Pharmaceutical pay a dividend?
Eton Pharmaceutical does not currently pay a regular dividend.
Is Eton Pharmaceutical a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 80.75, which implies 32.7% upside from the current price. This is not investment advice.
What is Eton Pharmaceutical's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Eton Pharmaceutical a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
Eton Pharmaceutical discussion 0 comments